aDepartment of Neuroscience
bDepartment of Molecular Medicine, Clinical Neurogenetics Unit
dHUBIN Project, Department of Clinical Neuroscience, Psychiatry Section
eDepartment of Nursing
fDepartment of Clinical Neuroscience, Clinical Alcohol and Drug Addiction Research Section
gDepartment of Clinical Neuroscience, Neurology Section, Karolinska Institutet, Stockholm, Sweden
cAlbert Einstein College of Medicine, Bronx, New York, USA
*Present address: AstraZeneca R&D, Södertälje, Sweden.
Sponsorship: Supported by the Swedish Research Council, Karolinska Institutet, the HUBIN project and the Wallenberg Foundation.
Correspondence to Lars Olson, Department of Neuroscience, Retzius Laboratory, Karolinska Institutet, Retzius väg 8, Stockholm, Sweden.
Tel: +46 8 7287050; fax: +46-8-323742; e-mail: [email protected]
Received 21 February 2002 Accepted 19 June 2002